In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux

Thrombosis Research

Volumn 129, Issue 4, 2012, Pages

  Samama, Meyer Michel ^a,b   Mendell, Jeanne ^c   Guinet, Céline ^b   Le Flem, Léna ^b   Kunitada, Satoshi ^d  

^a HÔTEL DIEU   (France)

^b Eurocopter   (France)

^c DAIICHI SANKYO INC   (United States)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; FONDAPARINUX; THROMBIN; THROMBOPLASTIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; DRUG SCREENING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE POOR PLASMA;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; POLYSACCHARIDES; PYRIDINES; THIAZOLES; THROMBIN;

EID: 84858335249     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.07.026     Document Type: Article

References (21)

1. J.I. Weitz New oral anticoagulants in development Thromb Haemost 103 1 2010 62 70
2. Arixtra [package insert] 2010 GlaxoSmithKline Research Triangle Park, NC
3. B.I. Eriksson, D.J. Quinlan, and J.I. Weitz Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin Pharmacokinet 48 1 2009 1 22
4. A.G. Turpie New oral anticoagulants in atrial fibrillation Eur Heart J 29 2 2007 155 165
5. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, and T. Nagahara DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J Thromb Haemost 6 9 2008 1542 1549
6. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Masumoto, T. Oguma, and M. Kojima Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 7 2010 743 753
7. M.U. Zafar, D.A. Vorchheimer, J. Gaztanaga, M. Velez, D. Yadegar, and P.R. Moreno Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber Thromb Haemost 98 4 2007 883 888
8. P.C. Wong, P.C. Crain, B. Xin, R.R. Wexler, P.Y.S. Lam, and D.J. Pinto Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies J Thromb Haemost 6 2008 820 829
9. A. Calatzis, D. Peetz, S. Haas, M. Spannagl, K. Rudin, and M. Wilmer Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors Am J Clin Pathol 130 2008 446 454
10. M. Hinder, A. Frick, P. Jordaan, G. Hesse, A. Gebauer, and J. Maas Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease Clin Pharmacol Ther 80 6 2006 691 702
11. M.M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma Thromb Haemost 104 5 2010 1078 1079
12. J.J. van Veen, A. Gatt, and M. Makris Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142 2008 889 903
13. E. Berntorp, and G. Salvagno Standardization and clinical utility of thrombin-generation assays Semin Thromb Hemost 34 7 2008 670 682
14. T. Baglin The measurement and application of thrombin generation Br J Haematol 130 2005 653 661
15. M.M. Samama, J.-L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 4 2010 815 825
16. T. Orfeo, S. Butenas, K.E. Brummel-Ziedins, M. Gissel, and K.G. Mann Anticoagulation by factor Xa inhibitors J Thromb Haemost 10 2010 1745 1753
17. A. Tripodi, V. Chantarangkul, C. Guinet, and M.M. Samama The International Normalized Ratio calibrated for Rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in-vitro study J Thromb Haemost 9 2011 226 228
18. E. Merriman, Z. Kaplan, E. Malan, E. Gan, and H. Tran Rivaroxaban and false positive lupus anticoagulant testing Thromb Haemost 105 2011 385 386
19. M.M. Samama, J.L. Martinoli, E. Perzborn, and T.E. Spiro Evaluation of rivaroxaban calibrators and controls and the prothrombin time for measuring rivaroxaban plasma concentrations [abstract 0688] Haematologica 95 suppl 2 2010 289
20. G. Raskob, A. Cohen, B. Eriksson, D. Puskas, M. Shi, and T. Bocanegra Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study Thromb Haemost 104 3 2010 642 649
21. T. Fuji, S. Fujita, S. Tachibana, and Y. Kawai A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty J Thromb Haemost 8 2010 2458 2468